This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Amyloid-targeting therapy has recently become widely available in the United States for the treatment of patients with symptomatic mild Alzheimer disease (AD). At present, there are no biomarkers that have been clinically validated to assess treatment response in routine clinical practice; longitudinal amyloid PET could play a role but is not cost-effective. This report presents a case series of 6 patients with AD, whose amyloid positivity was confirmed by PET or CSF biomarkers, who underwent baseline and longitudinal arterial spin-labeling MR imaging (ASL-MR) as part of Food and Drug Administration-mandated, clinical standard-of-care, noncontrast MR monitoring to assess for amyloid-related imaging abnormalities (ARIA). We and others have previously reported that ASL-MR can screen for neurodegenerative disease as a proxy for FDG-PET and can be easily added on as a cost-effective, repeatable method to monitor post therapy changes. This series highlights varied CBF changes in response to lecanemab therapy. For instance, Cases 1, 3, and 5 showed increased CBF after multiple infusions, with subjective cognitive improvement in Case 1 and improved MoCA scores in Case 3. Case 2 showed improved CBF initially before the fifth infusion, but this returned to baseline in the subsequent study, with no cognitive improvement over the course of therapy. Cases 4 and 6 have demonstrated no substantial changes in regional CBF thus far on therapy, with cognitive decline in Case 4. This case series underscores the potential utility of ASL-MR as an adjunct sequence to current imaging protocols to monitor treatment response to antiamyloid therapy.

Key findings

Cases 4 and 6 have demonstrated no substantial changes in regional CBF thus far on therapy, with cognitive decline in Case 4.

Why it matters

This case series of 6 patients on lecanemab found varied changes in cerebral blood flow on arterial spin-labeling MRI, with some cases showing increased flow and cognitive improvement and others showing no substantial change or cognitive decline. The authors present this as a potential longitudinal biomarker of treatment response, but the small number of cases means it is preliminary.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 44/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (American Journal of Neuroradiology)
Journal's citation record	2 / 4	American Journal of Neuroradiology: journal h-index 182 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Gloria Chia-Yi Chiang: h-index 36 (OpenAlex, whole career)
Institution's track record	1 / 3	Weill Cornell Medicine: institution h-index 1,163 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39805666)
Free to read	2 / 2	Free to read
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Ricaurte‐Fajardo, A., Ivanidze, J., Zhang, D., Mahmud, M., Yasen, W., Ravdin, L., et al. (2025). Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response? American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a8654

Vancouver

Ricaurte‐Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, et al. Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response? American Journal of Neuroradiology. 2025. doi:10.3174/ajnr.a8654. PMID: 39805666.

BibTeX

@article{ricaurtefajardo2025-39805666,
  author  = {Ricaurte‐Fajardo, Andres and Ivanidze, Jana and Zhang, D. and Mahmud, Meem and Yasen, Weiye and Ravdin, Lisa and Pahlajani, Silky and de Leon, Mony and others},
  title   = {{Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?}},
  journal = {American Journal of Neuroradiology},
  year    = {2025},
  doi     = {10.3174/ajnr.a8654},
  pmid    = {39805666},
  url     = {https://doi.org/10.3174/ajnr.a8654}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Treatments

See all studies in Treatments →